Like drug manufacturers, device makers have been criticized for the cost of their products and the role of those costs in increasing health spending. The industry has responded by releasing an actuarial study examining medical device spending. (AdvaMed Paper) Using Census Bureau data, the researchers say that in 2011, $159.4 billion was spent on medical devices and in vitro diagnostics, or 5.9% of national health spending. During a 23 year period from 1989 to 2011, device costs rose from 5.3% of spending to that 5.9% level, but since 1992 the share of spending accounted for by devices has basically been flat. Since 1992, device spending has increased at an average rate of 6.1% annually, almost exactly in line with the growth in overall health spending. At the same time, the unit prices for medical devices grew more slowly than medical or general CPI, meaning all the growth in spending must have been accounted for by utilization gains. While the authors suggest that this may reflect the competitive nature of the industry, it may also be due to the fact that the bulk of medical device reimbursement comes from government programs which set prices by fiat and tend to raise them very slowly. It likely also is caused by the industry setting high initial prices and seeing margins stay stable or even growth as cost of goods and other expenses come down with volume growth. The issue with device spending, as with drugs, may not be how often they are used or how appropriately, but whether the margins are justified. Based on public company financials, gross margins are often in the 70% to 80% range, meaning the products only cost about 20% to 30% of the price received. The remainder goes to selling, marketing and administrative expenses and profit margins. The size of these expenses and margins is where the focus should be and lower prices would obviously result in less spending. It should be noted that the data used is not derived from actual payer information on reimbursements, which would be the most accurate way to measure real-world spending and spending growth. The researchers failure to use this data, which is hard to extract, also calls into question their conclusion on price growth. The most that can be said for the device category of health spending is that it hasn’t been an outsized contributor to the cost problem, but it hasn’t been a non-factor.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Mercer, a large benefits consulting firm, confirms that health plan premiums are rising in 2023, publishing survey results showing that employers expect an increase of costs by at least 5%....
December 9, 2022
More money pouring into young health care companies as Dispatch Health gains $330 million in new capital to deliver high acuity health care in a patient’s home, rather than a...
November 30, 2022
A lot of money is invested in health care startups and growth companies, since health care is 20% of the economy, but the returns aren’t always good. Here is another...
November 1, 2022
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace